Effect of a Standardized Extract of Asparagus officinalis Stem (ETAS®50) on Cognitive Function, Psychological Symptoms, and Behavior in Patients with Dementia: A Randomized Crossover Trial
Table 2
Between-group comparisons of the initial and final scores and differences in scores for each assessment method (n = 27).
ETAS®50 period
Initial
Final
Difference
MMSE
21.00 ± 5.19
21.48 ± 5.69
0.48 ± 2.33
CDT
11.60 ± 4.33
11.80 ± 4.51
−0.28 ± 4.23
NPI-Q-a
2.50 ± 3.44
1.96 ± 3.23
−0.56 ± 1.72
NPI-Q-b
2.70 ± 4.64
2.48 ± 4.76
−0.26 ± 1.29
QOL
42.89 ± 5.03
42.89 ± 4.93
0.00 ± 3.57
SDS
34.93 ± 6.35
34.56 ± 7.44
−0.37 ± 4.56
Placebo period
Differencevalue
Initial
Final
Difference
21.11 ± 5.06
21.00 ± 5.97
−0.11 ± 2.68
0.420
11.80 ± 3.75
11.89 ± 4.64
0.09 ± 2.49
0.827
2.20 ± 3.30
2.89 ± 4.85
0.67 ± 2.34
0.045
2.60 ± 4.42
3.00 ± 5.97
0.44 ± 2.31
0.472
43.37 ± 4.72
43.56 ± 4.71
0.19 ± 4.20
0.903
34.89 ± 7.38
32.82 ± 7.02
−2.07 ± 6.70
0.327
values <0.05 compared to the initial and final scores are considered statistically significant.
